Last Update 24 Jan 26

Fair value Decreased 0.019%

ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment

Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler.

Analyst Commentary

Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.

Bullish Takeaways

Bullish analysts view the US$9 target as support for further upside from current levels, assuming the company can deliver on the revenue and margin assumptions embedded in recent models.
The initiation at what is, in effect, a premium to the revised US$6.50 target suggests some analysts see room for the P/E multiple to hold or expand if management executes on its plan.
Supportive views center on the idea that current expectations already account for near term risks, so any positive surprises on growth or profitability could have an outsized impact on valuation.
Some bullish analysts also point to the potential for sentiment to improve if the company delivers consistent progress against the financial assumptions now reflected across Street research.

Bearish Takeaways

Bearish analysts focus on the gap between the US$6.50 and US$9 targets, viewing it as a sign that there is still meaningful uncertainty around execution on growth and margin goals.
There is caution that the current P/E assumptions may prove demanding if revenue or profitability trends fall short of the updated expectations now embedded in the higher target.
More cautious views highlight that, with targets already reset using updated revenue and profit margin assumptions, there may be limited room for error before valuation needs to be revisited.
Some bearish analysts stress that without clear visibility on how quickly the company can align actual results with these modeled assumptions, the stock could remain volatile around earnings and guidance updates.

What's in the News

Esperion is actively seeking acquisitions that are financially affordable, nondilutive and intended to be immediately accretive, with a focus on assets that are approved or close to approval rather than earlier stage clinical programs, according to CEO Sheldon Koenig at the 44th Annual Healthcare Conference (Key Developments).
Management reports having screened many potential targets and held multiple discussions with organizations, indicating an ongoing process to identify a transaction that aligns with the company’s financial and product criteria (Key Developments).
Otsuka Pharmaceutical has launched NEXLETOL tablets in Japan for hypercholesterolemia and familial hypercholesterolemia after receiving National Health Insurance Price Listing, triggering a US$90 million near term payment to Esperion under their collaboration and license agreement (Key Developments).
Under the Otsuka collaboration, Esperion is also eligible for additional sales milestone payments tied to total net sales in Japan, as well as tiered royalties of 15% to 30% on those net sales (Key Developments).
Esperion presented two post hoc analyses from the CLEAR Outcomes trial at the 2025 American Heart Association Scientific Sessions, including data on bempedoic acid monotherapy in around 8,200 patients without background lipid lowering therapy and an analysis of venous thromboembolism risk compared with placebo (Key Developments).

Valuation Changes

Fair Value: essentially unchanged, moving fractionally from US$6.5025 to US$6.50125 per share.
Discount Rate: steady, with a minimal adjustment from 6.956% to 6.956%.
Revenue Growth: higher assumptions, shifting from 20.39% to 22.19%.
Net Profit Margin: slightly higher, moving from 26.69% to 27.23%.
Future P/E: reduced modestly, moving from 16.31x to 15.29x.

13 views

Key Takeaways

Growing adoption of cholesterol therapies, international partnerships, and improved patient access are expected to drive sustained revenue and margin growth.
Extended patent protection and pipeline expansion reduce near-term risks and offer long-term growth opportunities through new treatment indications.
Heavy reliance on a narrow product lineup, growing competitive threats, pricing pressures, and high costs create ongoing risks to market share, profitability, and financial stability.

Catalysts

About Esperion Therapeutics

A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.What are the underlying business or industry changes driving this perspective?

Accelerating adoption of NEXLETOL and NEXLIZET among statin-intolerant patients, supported by digital/direct marketing campaigns and growing awareness, positions Esperion to benefit from broader trends in proactive cholesterol management among younger and older populations-driving sustained prescription volume and revenue growth.
International expansion through partnerships with companies like Daiichi Sankyo (Europe), Otsuka (Japan), HLS (Canada), and others, along with milestone and royalty income from new country launches, is expected to diversify and stabilize revenue streams as global cardiovascular disease incidence rises.
Improving access dynamics-including expanded payer coverage, reductions in prior authorization hurdles, and higher prescriber approval rates-support increased patient access to Esperion's therapies, likely leading to higher net revenues and margin improvement over time as fixed costs are leveraged.
Successful settlements with generic manufacturers extend patent protection for NEXLETOL in the U.S. to 2040, reducing near
and medium-term generic erosion risk and providing a longer runway for top-line growth and sustained profitability.
Pipeline expansion into new, high-value indications (such as primary sclerosing cholangitis) and potential launches of next-generation or combination therapies leverage the global shift toward oral, preventive care treatments, offering upside to future revenue and gross margin potential.

Esperion Therapeutics Earnings and Revenue Growth

Esperion Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Esperion Therapeutics's revenue will grow by 18.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -38.8% today to 23.7% in 3 years time.
Analysts expect earnings to reach $106.1 million (and earnings per share of $0.49) by about September 2028, up from $-104.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $145.1 million in earnings, and the most bearish expecting $-109.6 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 14.6x on those 2028 earnings, up from -4.7x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 2.33% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.22%, as per the Simply Wall St company report.

Esperion Therapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Esperion's future growth relies heavily on continued uptake of its flagship products NEXLETOL and NEXLIZET among statin-intolerant patients; given that its pipeline and new indications remain early-stage, this product concentration creates material revenue risk should competition intensify or prescribing trends shift away from their core franchise.
The emergence of novel oral non-statin LDL-lowering competitors (such as oral PCSK9 inhibitors or CETP inhibitors) poses a significant long-term threat; if these competitors deliver positive cardiovascular outcomes and/or secure broader indications (including primary prevention), Esperion's market share and pricing power could erode, directly pressuring both revenue growth and net margins.
Despite notable recent progress, Esperion continues to face drug pricing pressures from payers and potential reductions in Medicare/Medicaid spend; as value-based care contracts and government scrutiny on drug costs escalate, the company may be forced to lower prices or offer larger discounts, impacting profitability and earnings consistency.
While Esperion touts intellectual property settlements extending U.S. market exclusivity to 2040 for NEXLETOL, ongoing and future patent challenges, as well as eventual generic entry internationally, could compress margins and reduce longer-term predictability of cash flows and bottom-line earnings, especially beyond current guidance windows.
Persistent high SG&A costs, modest R&D allocation, and recent achievement of operating income (rather than sustained profitability) leave Esperion reliant on continuous double-digit top-line growth and milestone payments; any setbacks in international launches, regulatory approvals, or slower-than-expected adoption could undermine the transition to sustainable profitability and may necessitate dilutive capital raises to maintain financial flexibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $5.8 for Esperion Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $16.0, and the most bearish reporting a price target of just $1.6.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $447.8 million, earnings will come to $106.1 million, and it would be trading on a PE ratio of 14.6x, assuming you use a discount rate of 7.2%.
Given the current share price of $2.43, the analyst price target of $5.8 is 58.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Esperion Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rising Digital Adoption And Global Partnerships Will Shape Future Markets